Cocrystal Pharma
Cocrystal Pharma is a biotechnology company that specializes in the discovery and development of antiviral therapeutics aimed at treating serious viral diseases. The company utilizes structure-based technologies to create innovative antiviral drugs targeting the replication machinery of viruses such as hepatitis C, influenza, and norovirus. Cocrystal is advancing CC-31244, a non-nucleoside polymerase inhibitor currently in Phase 2a clinical trials for hepatitis C. Additionally, CC-42344, a PB2 inhibitor for influenza, is in preclinical development. Cocrystal has established a collaboration agreement with Merck Sharp & Dohme Corp. for the development of proprietary influenza antiviral agents, as well as a licensing agreement with Kansas State University Research Foundation to create antiviral compounds for norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.
RFS Pharma, LLC is a clinical-stage biopharmaceutical company founded by Dr. Raymond F. Schinazi, dedicated to developing innovative treatments for hepatitis infections and emerging viruses. Based in Tucker, Georgia, the company operates from a laboratory facility that focuses on biotechnological development and research capabilities, particularly in antiviral agents and nucleoside chemistry. Since its incorporation in 2004, RFS Pharma has made significant strides in the pharmaceutical sector, notably in-licensing anti-hepatitis technology from Emory University in 2013. The company is also actively exploring opportunities to in-license promising new drugs to expand its pipeline and contribute to advancements in the pharmaceutical industry.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.